This document has been prepared in accordance with accounting principles and practices generally accepted in Japan, and translated for reference only from the original Japanese version. The Company gives no warranty with respect to its correctness.
The original disclosure in Japanese was released on December 15, 2016
Takara Holdings Inc.
Notice Regarding Signing of Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for the Investigational Cancer Treatment HF10, an Oncolytic Virus, by a Consolidated Subsidiary of Takara Holdings (Takara Bio Inc.)
Takara Bio Inc. (The First Section of Tokyo Stock Exchange, securities code number: 4974), a consolidated subsidiary of the Company, today issued a news release announcing that they had signed Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for the Investigational Cancer Treatment HF10, an Oncolytic Virus.
The impact of the agreement on consolidated earnings for the fiscal year ending March 31, 2017 is currently being assessed along with other factors. Should it be judged necessary for performance forecasts to be revised, notice will be given in a timely manner.
